Akero Therapeutics is a clinical stage biopharmaceutical company focused on delivering transformational medicines to patients with high unmet medical need. Our current focus is on advancing our lead program efruxifermin (EFX) to provide a powerful new treatment for patients with MASH, a disease for which there are few effective treatment options.
Corporate Presentation
Corporate Presentation
Share Price
Akero Therapeutics
Nov 20, 2024 5:41 PM EST
Data Provided by Refinitiv. Minimum 15 minutes delayed.
Data Provided by Refinitiv. Minimum 15 minutes delayed.